These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12215758

  • 1. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J, Fenyvesi T, Jörg I.
    Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
    [Abstract] [Full Text] [Related]

  • 2. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 3. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J, Kiesewetter H, Jörg I, Harenberg J.
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [Abstract] [Full Text] [Related]

  • 4. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, THRIVE Treatment Study Investigators.
    JAMA; 2005 Feb 09; 293(6):681-9. PubMed ID: 15701909
    [Abstract] [Full Text] [Related]

  • 5. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 6. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 30; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep 30; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 9. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug 30; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 10. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S.
    Pathophysiol Haemost Thromb; 2005 Aug 30; 34 Suppl 1():18-24. PubMed ID: 15812200
    [Abstract] [Full Text] [Related]

  • 11. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV, Bounameaux H.
    Semin Vasc Med; 2005 Aug 30; 5(3):276-84. PubMed ID: 16123915
    [Abstract] [Full Text] [Related]

  • 12. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H.
    Thromb Haemost; 2005 Oct 30; 94(4):820-4. PubMed ID: 16270637
    [Abstract] [Full Text] [Related]

  • 13. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J, Jörg I, Weiss C.
    Int J Toxicol; 2006 Oct 30; 25(3):165-9. PubMed ID: 16717032
    [Abstract] [Full Text] [Related]

  • 14. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Oct 30; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P, Simioni P, Pagnan A.
    Minerva Cardioangiol; 2003 Aug 30; 51(4):361-71. PubMed ID: 12900718
    [Abstract] [Full Text] [Related]

  • 16. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Colwell CW, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW, EXULT B Study Group.
    J Bone Joint Surg Am; 2005 Oct 30; 87(10):2169-77. PubMed ID: 16203879
    [Abstract] [Full Text] [Related]

  • 17. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA, Dorrell KA, Sandberg KR, Yerkey MW.
    Rev Cardiovasc Med; 2004 Oct 30; 5(2):99-103. PubMed ID: 15184843
    [Abstract] [Full Text] [Related]

  • 18. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L, Boucher M.
    Issues Emerg Health Technol; 2004 Jun 30; (57):1-4. PubMed ID: 15214359
    [Abstract] [Full Text] [Related]

  • 19. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 30; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 20. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S, THRIVE III Investigators.
    Br J Haematol; 2006 Apr 30; 133(1):68-77. PubMed ID: 16512831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.